DePuy Synthes
 | |
| Company type | Subsidiary |
|---|---|
| Industry | |
| Founded | 1895 |
| Founders | Revra DePuy |
| Headquarters | 325 Paramount Drive, , U.S. |
Area served | Worldwide |
Key people | Michael M. Schulman (CFO) |
| Products | Replacement knees, hips, biomaterials |
| Parent | Johnson & Johnson |
| Website | depuysynthes |
DePuy Synthes (/dəˈpjuː/) is a franchise of orthopaedic and neurosurgery companies. Acquired by Johnson & Johnson in 1998, its companies form part of the Johnson & Johnson MedTech business segment. DePuy develops and markets products under the Codman, DePuy Mitek, DePuy Orthopaedics and DePuy Spine brands.
DePuy Orthopaedics designs, manufactures, markets and distributes products for reconstructing damaged or diseased joints and for repairing and reconstructing traumatic skeletal injuries. DePuy Spine products facilitate fusion of the spine and correction of spinal deformities, preserving motion of the spine and repairing bone fractures.
DePuy is now operating from several countries, including the United Kingdom, Japan, France, Germany, Ireland and Australia. In many other countries, DePuy operates as a brand under the Johnson & Johnson Medical organization.[1]
DePuy is currently the subject of more than 11,000 lawsuits related to its recall of faulty hip replacement systems, which lawyers and industry analysts estimate will cost parent company Johnson & Johnson billions of dollars to resolve.[2]
History
[edit]Founded 1895 in Warsaw, Indiana, by Revra DePuy, DePuy Manufacturing began designing and building fiber splints to replace wooden barrel staves that were used to set fractures.[3]
On April 22, 2008, the DePuy franchise and Johnson & Johnson Medical marked the official opening of Johnson & Johnson Medical (Suzhou), Ltd., establishing production facilities in China for DePuy and the J&J Family of Companies. At 120,000 square feet (11,000 m2), this facility occupies a fraction of the J&J campus, which encompasses 69 acres (280,000 m2) in total. Manufacturing at JJM began in February 2008.
On August 24, 2010, DePuy recalled[4] all ASR hip implant systems sold since 2003. The 2010 DePuy Hip Recall was issued after research released by the National Joint Registry (NJR) found high rates of hip replacement failure for the ASR XL Acetabular and ASR Hip Resurfacing systems. Another study noted the high rate of failure in patients who received ASR XL hip arthroplasty.[5] In August 2013, attorneys for thousands of patients who received the implants sent a letter to the Food and Drug Administration accusing the company of breaking federal law by hiding experts’ misgivings about the device, and called on the agency to investigate. “We believe almost all of these injuries would have been avoided had DePuy complied with the reporting requirements and informed your agency about the adverse events and concerns about the safety of the ASR which came to the company’s attention,” the attorneys said.[6] DePuy faces more than 11,000 plaintiffs nationwide over the ASR XL, which generally allege that the product is prone to degrading prematurely and shedding toxic metal debris, causing pain and necessitating revision surgeries that can be more invasive than the initial total hip replacements. In the first trial related to the product, a California jury awarded $8.3 million in compensatory damages to a retired prison guard, finding the implant's design to be faulty and DePuy to have acted negligently. A judge later upheld the jury verdict on post-trial motions. In the second trial, an Illinois jury returned a verdict in favor of DePuy in a lawsuit brought by a nurse who had sought $5 million in damages.[7]
On June 14, 2012, Johnson & Johnson completed the acquisition of Synthes, which was integrated with the DePuy franchise to establish the DePuy Synthes Companies of Johnson & Johnson.[8] Subsequently, the company's logo changed from its previous characteristic red-dot. In 2017, Codman Neurosurgery, part of Depuy Synthes, was acquired by medical device maker Integra LifeSciences for $1.045 billion.[9]
On September 14, 2023, Johnson & Johnson announced its MedTech and pharmaceutical segments were uniting under the Johnson & Johnson brand name.[10]
Operating companies
[edit]- Codman & Shurteff, Inc.
- DePuy Mitek, Inc.
- DePuy Orthopaedics, Inc.
- DePuy Spine, Inc
References
[edit]- ^ Hermann Simon mentioned this company in his correspondent Book as an example of a "Hidden Champion" (Simon, Hermann: Hidden Champions of the 21st Century : Success Strategies of unknown World Market Leaders. London: Springer, 2009.- ISBN 978-0-387-98147-5.)
- ^ Meier, Barry (8 March 2013). "J.&J. Loses First Case Over Faulty Hip Implant". New York Times. Retrieved 5 September 2013.
- ^ "DePuy, a Johnson & Johnson Company" (PDF). Indiana Historical Society. Archived from the original (PDF) on 2016-07-29. Retrieved 2012-10-12.
- ^ Johnson, Linda A. (2010-08-27). "J&J unit recalls hip replacement products". Usatoday.Com. Retrieved 2012-08-13.
- ^ Bernthal, Nicholas; Paul Celestre; Alexandra Stavarkis; John Ludington; Daniel Oakes (2012). "Disappointing Short-Term Results With the DePuy ASR XL Metal-on-Metal Total Hip Arthroplasty". Journal of Arthroplasty. 27 (4): 539–544. doi:10.1016/j.arth.2011.08.022. PMID 22000575.
- ^ Scurria, Andrew (27 August 2013). "Reporter". Law 360. Retrieved 28 August 2013.
- ^ Scurria, Andrew (27 August 2013). "Legal Reporter". Law 360. Retrieved 28 August 2013.
- ^ "Johnson & Johnson Announces Completion of Synthes Acquisition". 14 June 2012. Johnson and Johnson. Retrieved 28 August 2013.
- ^ Newmarker, Chris (October 2, 2017). "Integra LifeSciences completes purchase of J&J's Codman Neurosurgery". Mass Device. Archived from the original on 2017-10-03.
- ^ "Johnson & Johnson Announces New Pharmaceutical and MedTech Business Segment Branding". Endovascular Today. Retrieved 2024-11-11.